Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Di | BTIG initiates Maze Therapeutics stock with Buy rating on kidney disease potential | 1 | Investing.com | ||
Di | Maze Therapeutics names new finance chief | 1 | Seeking Alpha | ||
Di | Misbah Tahir wird neuer CFO bei Maze Therapeutics | 1 | Investing.com Deutsch | ||
Di | Maze Therapeutics Names Misbah Tahir As CFO | 1 | RTTNews | ||
Di | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer | 122 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
Di | Maze Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
28.08. | Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex | 24 | FiercePharma | ||
12.08. | Maze Therapeutics, Inc.: Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | 88 | GlobeNewswire (Europe) | MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrolling... ► Artikel lesen | |
12.08. | Maze Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.07. | H.C. Wainwright startet Coverage für Maze Therapeutics mit "Buy"-Rating und Kursziel von 34 US-Dollar | 2 | Investing.com Deutsch | ||
23.07. | H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating | - | Investing.com | ||
14.05. | Maze Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.05. | Maze Therapeutics, Inc.: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones | 146 | GlobeNewswire (Europe) | MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong... ► Artikel lesen | |
31.03. | Maze Therapeutics GAAP EPS of -$18.32 | 3 | Seeking Alpha | ||
31.03. | Maze Therapeutics, Inc.: Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights | 282 | GlobeNewswire (Europe) |
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised... ► Artikel lesen | |
31.03. | Maze Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
31.03. | Maze Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.02. | Maze Therapeutics, Inc.: Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease | 290 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop... ► Artikel lesen | |
31.01. | Maze Therapeutics Prices Upsized IPO Of 8.75 Mln Shares At $16.00/shr | 808 | AFX News | WASHINGTON (dpa-AFX) - Maze Therapeutics Inc. (MAZE) announced that it has priced its upsized initial public
offering of 8.75 million shares of its common stock at a public offering price... ► Artikel lesen | |
31.01. | Maze Therapeutics, Inc.: Maze Therapeutics Announces Pricing of Upsized Initial Public Offering | 162 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,215 | +0,11 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.08.2025 - 15.15 Uhr | ROUNDUP: Gerresheimer bekommt überraschend neuen Finanzchef - Aktie erholt DÜSSELDORF - Der zuletzt schwächelnde Pharmaverpackungshersteller Gerresheimer bekommt überraschend einen neuen Finanzchef.... ► Artikel lesen | |
ADMA BIOLOGICS | 16,905 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
EVOTEC | 5,702 | -2,70 % | Insiderkäufe und Datenpanne - Evotec, naoo AG, PayPal | In der deutschen Wirtschaft herrscht zunehmend Unruhe und nicht jeder Vorstand sitzt mehr sicher im Sattel. Der Volkswagen Konzern ist ins Straucheln geraten und die Frage, ob der Vorstandschef Oliver... ► Artikel lesen | |
VERA THERAPEUTICS | 21,900 | -4,62 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 35,510 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
STRUCTURE THERAPEUTICS | 19,760 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 33,175 | 0,00 % | Mineralys Therapeutics closes $287.5 million public offering | ||
TAYSHA GENE THERAPIES | 3,260 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | |
APOGEE THERAPEUTICS | 37,130 | -2,75 % | Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum | ||
PRAXIS PRECISION MEDICINES | 46,090 | -1,01 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
IMMUNOME | 9,800 | -4,39 % | Immunome Inc. - 10-Q, Quarterly Report | ||
PHATHOM PHARMACEUTICALS | 12,000 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
BIONTECH | 89,10 | +3,42 % | BioNtech Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
EDGEWISE THERAPEUTICS | 14,620 | -0,10 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,805 | 0,00 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress |